• DOI:10.1007/s00280-005-1033-0
Corpus ID: 27576150

Is there a pharmacological basis for differences in 5-HT3-receptor antagonist efficacy in refractory patients?

@article{Wit2005IsTA,
  title={Is there a pharmacological basis for differences in 5-HT3-receptor antagonist efficacy in refractory patients?},
  author={R. de Wit and M. Aapro and P. Blower},
  journal={Cancer Chemotherapy and Pharmacology},
  year={2005},
  volume={56},
  pages={231-238}
}

R. de Wit, M. Aapro, P. Blower

Published 2005

Medicine

Cancer Chemotherapy and Pharmacology

Abstract5-HT3-receptor antagonists are the current antiemetic ‘gold standard’ for chemotherapy- and radiotherapy-induced nausea and vomiting. Interestingly, studies have shown that patients experiencing poor control of acute chemotherapy-induced nausea and vomiting with one antiemetic therapy may respond well to another agent, including a drug of the same class. This review examines pharmacological differences between the 5-HT3-receptor antagonists in order to determine potential reasons for… CONTINUE READING

View on Springer

ncbi.nlm.nih.gov

Save to Library

Create Alert

Cite

Launch Research Feed